Glenmark Pharmaceuticals has informed that it has attached a media release on 4th June 2021 titled ‘Glenmark Pharmaceuticals receives ANDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity on the 450 mg’ which is self?explanatory.
The above information is a part of company’s filings submitted to BSE.